Ultrahuman today announced that it is expanding its blood vision service to more than 60 cities and 2,000 pin codes across India. The expansion aims to provide millions of users with affordable access to the company’s premium preventive health services. The company has also launched Vision Cloud, which is claimed to be the world’s first free universal health interpreter, and allows users to upload past blood test results and get personalized insights within the UltraHuman app.
Through the partnership with Tata 1MG, Ultrahuman Blood Vision will offer at-home sample collection by trained phlebotomists. Blood Vision offers 15 curated test panels, with prices starting at ₹999. The base plan (₹1,999) includes over 60 essential biomarkers, while the premium plan includes 100+ advanced markers across cardiovascular, metabolic, hormonal and longevity pathways.
blood sight
Blood vision results are delivered directly within the UltraHuman app, eliminating the need for PDFs. Each marker is accompanied by a reference range and actionable insights, enhanced by the company’s UltraTrace technology that integrates lifestyle data from the Ultrahuman Ring AIR. This data helps users track their well-being based on a variety of factors, including sleep, activity, and recovery, and provides personalized health recommendations based on their results.
ultrahuman ring air
10% off with our code: gsm10
Read our review
£296 at Ultrahuman UK
UltraHuman’s new Vision Cloud feature supports users by offering free, AI-powered interpretations of past blood test reports. The tool provides personalized health analysis, including supplement recommendations and blood age scores. Vision Cloud will expand in the future to interpret additional diagnostic data, including microbiome, cancer, CT scans, and MRI, with the goal of building a fully integrated health ecosystem for users globally.
This expansion into India marks a significant milestone in Ultrahuman’s global strategy, which already includes operations in Saudi Arabia and the UAE, with future launches planned for the UK and Australia. The company also plans to expand its interpretation capabilities to include genetics, microbiome data and lifestyle risk profiling in the near future.